AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02649166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
Study NCT02649166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop deep brain stimulation
Description: The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
Study NCT00397501 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Trastuzamab, 6mg/kg, within 48 hrs before BBBD~Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles
Study NCT00397501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: 200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
Study NCT00397501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
Study NCT00397501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium thiosulfate
Description: STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
Study NCT03807986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nanofat grafting
Description: Nanofat grafting will be applied once every three months for 2 times.
Study NCT03807986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfat grafting
Description: Microfat grafting will be applied once every three months for 2 times.
Study NCT03807986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) Injection
Description: PRP Injection will be applied once a month for 6 times.
Study NCT02850484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Inhaled corticosteroid
Study NCT02850484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhaled corticosteroid
Study NCT02850484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)
Study NCT02850484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Long Acting Beta Agonist (LABA)
Study NCT03046693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A Citicoline 1000 mg oral tablet
Description: Citicoline 1000 mg will be repackaged and given to Group A for 60 days
Study NCT03046693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group B placebo oral tablet
Description: Placebo will be repackaged and given to Group B for 60 days
Study NCT00714545 — intervention group
Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Intracoronary brachytherapy
Description: Beta irradiation with a 40-mm strontium/lytrium-90 source
Study NCT01242423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave therapy
Description: ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
Study NCT03361137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit. Dosing was to be adjusted if the participant had a significant change in body weight.
Study NCT01235897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
Study NCT01235897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 weekly - paclitaxel
Study NCT01235897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
Study NCT02250222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGD-6972
Description: LGD-6972 sodium salt powder in Captisol ® (betadex \[β-cyclodextrin\] sulfobutylether sodium, NF)
Study NCT02250222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Captisol ®)
Description: betadex \[β-cyclodextrin\] sulfobutylether sodium, NF
Study NCT02898818 — intervention group
Intervention type: OTHER
Intervention: vaginal and oral swab sample, questionnaire
Description: vaginal and oral swab sample and questionnaire
Study NCT02898818 — intervention group
Intervention type: OTHER
Intervention: papa smear
Description: Papnicolaou Papa Smear test
Study NCT02018562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portex Blueline Ultra Suctionaid Tracheostomy Tube
Study NCT03497637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: measurement of FFR
Description: use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
Study NCT03497637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: measurement of Pd/Pa
Description: use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
Study NCT04448886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: (iv) fixed dose, administered once per cycle
Study NCT04448886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: (iv) fixed dose, administered twice per cycle
Study NCT00001711 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: scan of healthy volunteers.
Study NCT06253832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conservative surgery for placenta accreta spectrum
Description: The surgical procedure involved a midline incision for the laparotomy approach. Dissection of the uterus from the posterior bladder wall extended down to the cervix, with coagulation of the vesicouterine vessels. Hysterotomy was executed in the upper segment, just above the area of myometrial invasion. Hemostasis of the lower uterus was achieved through either square compression sutures or ligation of the colpouterine vessels. A conservative approach to uterine surgery was considered viable only under conditions of stable hemodynamics and when at least 2 cm of healthy myometrium was visibly intact above the cervix. For cases involving conservative resection, all myometrium affected by invasion and the entire placenta were excised. Subsequently, the uterus was reconstructed using a continuous stitching technique.
Study NCT06253832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysterectomy
Description: hysterectomy for placenta accreta spectrum
Study NCT04245111 — intervention group
Intervention type: OTHER
Intervention: Immunofluorescence Imaging
Description: Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Pentero or Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
Study NCT03587844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.
Study NCT03587844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: LyP Brentuximab vedotin 0.9 mg/kg2
Study NCT03587844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
Study NCT03808974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Short educational video describing the mid-urethral sling procedure
Study NCT03808974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational leaflet
Description: Standard educational leaflet describing the mid-urethral sling procedure
Study NCT03299959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agili-C implant
Description: Agili-C implant
Study NCT03299959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SSOC
Description: microfracture and/or debridement
Study NCT03025971 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: J-Valve Transcatheter Aortic valve replacement
Description: Transapical Transcatheter Aortic Valve Replacement
Study NCT04381832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist
Study NCT04381832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is an anti-PD-1 antibody
Study NCT04381832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor.
Study NCT04381832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is an androgen receptor inhibitor
Study NCT04381832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide is an androgen receptor inhibitor
Study NCT04381832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is type of chemotherapy
Study NCT04381832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is type of chemotherapy
Study NCT04381832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG
Description: Sacituzumab govitecan is an antibody-drug conjugate
Study NCT02814006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health educational video
Description: visualization of health educational video
Study NCT02582021 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Angiography
Description: A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography.
Study NCT04486326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer
Description: Crofelemer
Study NCT02582021 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Reactivity Testing
Description: An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
Study NCT02582021 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Magnetic Resonance Imaging
Description: Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI.
Study NCT02582021 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Magnetic Resonance Angiography
Description: Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
Study NCT02582021 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Coronary Tomographic Angiography
Description: Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
Study NCT02582021 — intervention group
Intervention type: PROCEDURE
Intervention: Rest-Stress Millar Testing
Description: Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging.
Study NCT02582021 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic vasorelaxation tests
Description: Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
Study NCT04318977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-frequency rTMS
Description: repetitive transcranial magnetic stimulation
Study NCT04318977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBS
Description: theta burst stimulation
Study NCT04318977 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo transcranial magnetic stimulation
Study NCT03008291 — intervention group
Intervention type: PROCEDURE
Intervention: CRT-D Implantation
Description: Cardiac resynchronization therapy defibrillator
Study NCT03008291 — intervention group
Intervention type: PROCEDURE
Intervention: CRT-P Implantation
Description: Cardiac resynchronization therapy pacemaker
Study NCT03008291 — intervention group
Intervention type: PROCEDURE
Intervention: Dual Chamber Pacemaker Implantation
Study NCT04486326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01590082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
Study NCT01590082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
Study NCT01349608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephonic health coaching
Description: Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
Study NCT03751241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeTracker
Description: The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
Study NCT00837382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEDVAMC Nightmare Treatment
Description: Veteran Nightmare Treatment Using Imagery Rescripting
Study NCT00837382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepsychiatry Nightmare Treatment
Description: Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
Study NCT01590082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
Study NCT04767139 — intervention group
Intervention type: BEHAVIORAL
Intervention: counseling for family planning
Description: all mothers presented to infant immunization units of the selected health centers will be counseled for family planning service and referred to the family planning unit if they decided to use.
Study NCT04053036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will be given 1.5mg/kg of MDMA
Study NCT04053036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Participants will be given a placebo capsule that will only contain lactose.
Study NCT02262806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metreleptin
Description: A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
Study NCT03905707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glepaglutide
Description: Glucagon-Like Peptide-2 (GLP-2) analog
Study NCT01912677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Study NCT01912677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Study NCT01912677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa
Study NCT02305836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand.
Study NCT02305836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: cholinesterase inhibitors (ChE-Is)
Study NCT00294918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serostim®
Description: Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
Study NCT01996189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard needle BBraun Sterican® 23G and 25mm in length
Description: Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
Study NCT01996189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard needle BBraun Sterican® 23G and 25mm in length
Description: Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
Study NCT01996189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
Study NCT01996189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
Study NCT04493502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT01869907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 100 mg once daily by mouth during 14 days
Study NCT01869907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once daily by mouth during 14 days
Study NCT04493502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658
Description: Administered IV